Evidence map›Paper›PMID 40999649›Full record

ArticleCPT: pharmacometrics & systems pharmacology2025

Evaluation and Mitigation of Time-Dependent Confounding Effects in Conventional Exposure-Response Analyses for Oncology Drugs.

Xuefen Yin, Ye Xiong, Youwei Bi, Xin Wei, Hong Zhao, Elimika Pfuma Fletcher, Rajanikanth Madabushi, Amal Ayyoub, Hao Zhu, Stephan Schmidt and 1 more

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xuefen YinCenter for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0009-0006-1653-9192
Ye XiongCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0002-4473-0393
Youwei BiCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Xin WeiCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0003-4213-451X
Hong ZhaoCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Elimika Pfuma FletcherCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0002-0345-4230
Rajanikanth MadabushiCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Amal AyyoubCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Hao ZhuCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Stephan SchmidtCenter for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0000-0002-4998-1167
Jiang LiuCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0002-5755-3904

Funding

Office of Women's Health, FDA
6 · The paper itself

Abstract

Conventional exposure-response (E-R) analyses, such as logistic regression and time-to-event analysis using summary exposure metrics, are often conducted in oncology using data from the pivotal trial(s) with a single dose level to support dosing decisions. However, these E-R analyses, affected by multiple confounding factors, may mischaracterize true E-R relationships, potentially limiting their utility in dosing decisions. This study investigates potential mischaracterization in such analyses influenced by the following time-dependent confounding factors: exposure accumulation, dose modification patterns, and event onset time. We used a simulation-based approach to evaluate two E-R scenarios: ER1, where event time generated with a Weibull distribution is not affected by drug exposure, and ER2, where the response is driven by drug exposure via a joint PK-tumor size model. Our analyses indicate that when using time-dependent exposure metrics (e.g., average concentration till event/censoring), exposure accumulation tends to induce an inverse E-R trend, while dose modifications (interruptions/reductions) likely induce a positive E-R trend. Simulations suggest that employing static exposure metrics (e.g., first-cycle or steady-state) minimizes these biases. Additionally, adopting an Emax model aligned with the underground truth in ER2 in the E-R analyses could reduce bias. When significant dose modifications are present, including relevant data from a dose-range study and employing modified methods for time-dependent exposure derivation may help mitigate bias. Overall, using multiple exposure metrics (including static ones) to assess E-R consistency and interpreting the potential causal effects with totality of evidence (including dose-response results) should be implemented to better inform dosing decisions.

Indexed as

Antineoplastic AgentsNeoplasmsComputer SimulationConfounding Factors, EpidemiologicDose-Response Relationship, DrugHumansModels, BiologicalTime FactorsAntineoplastic Agentsbias controldose modificationexposure–responseoncology dosingPK accumulationtime‐dependent confounding factors

Identifiers

PMID40999649
PMCPMC12706399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.